Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Going Generic? McNeil “Exploratory Project” May Pave The Way

This article was originally published in The Pink Sheet Daily

Executive Summary

“Patriot” division is appearing at trade shows in an “intelligence-gathering” capacity, McNeil says. An in-house generic operation would provide J&J with a greater share of profits than “authorized” generic deals.

You may also be interested in...



J&J’s Poon Joins Management Triumvirate With Vice Chairman Appointment

Worldwide Chairman-Medicines & Nutritionals Christine Poon joins the Office of the Chairman, which includes CEO Weldon and CFO Darretta. Poon retains management responsibility for the pharmaceutical business.

J&J’s Poon Joins Management Triumvirate With Vice Chairman Appointment

Worldwide Chairman-Medicines & Nutritionals Christine Poon joins the Office of the Chairman, which includes CEO Weldon and CFO Darretta. Poon retains management responsibility for the pharmaceutical business.

Andrx Expects Concerta "Authorized" Generic From J&J's Patriot Unit, Third Party

In a citizen petition, Andrx requests FDA re-evaluate its policy concerning the marketing of "authorized" generic versions of brand drugs. Petition urges the agency to seek formal input from FTC and Justice Department on potential anticompetitive effects.

Related Content

Topics

UsernamePublicRestriction

Register

PS060676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel